mibefradil has been researched along with Local Neoplasm Recurrence in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Azimi, I; Dutta, T; Feng, Z; Gueven, N; Maklad, A; Sedeeq, M; Wilson, R | 1 |
Desai, AS; Desideri, S; Fisher, JD; Grossman, SA; Holdhoff, M; Leal, J; Lesser, GJ; Lieberman, FS; Lodge, MA; Nabors, LB; Read, WL; Schiff, D; Supko, JG; Wahl, RL; Walbert, T; Ye, X | 1 |
1 trial(s) available for mibefradil and Local Neoplasm Recurrence
Article | Year |
---|---|
Timed sequential therapy of the selective T-type calcium channel blocker mibefradil and temozolomide in patients with recurrent high-grade gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Calcium Channels, T-Type; Dacarbazine; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Mibefradil; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Survival Rate; Temozolomide; Young Adult | 2017 |
1 other study(ies) available for mibefradil and Local Neoplasm Recurrence
Article | Year |
---|---|
T-Type Calcium Channel Inhibitors Induce Apoptosis in Medulloblastoma Cells Associated with Altered Metabolic Activity.
Topics: Apoptosis; Calcium; Calcium Channel Blockers; Calcium Channels, T-Type; Cerebellar Neoplasms; Child; Humans; Medulloblastoma; Mibefradil; Neoplasm Recurrence, Local; Vincristine | 2022 |